litlas
Log inCreate account

Jeffrey I. Weitz

Active 1986–2025

Also published as
Jeffrey I. WEITZ
259
Papers
68,156
Citations
120
h-index
255
i10-index

Citations

Citations per year for Jeffrey I. Weitz1910: 3 citations1986: 1 citations1987: 2 citations1988: 5 citations1989: 25 citations1990: 21 citations1991: 21 citations1992: 24 citations1993: 41 citations1994: 43 citations1995: 35 citations1996: 43 citations1997: 61 citations1998: 98 citations1999: 99 citations2000: 111 citations2001: 151 citations2002: 153 citations2003: 241 citations2004: 215 citations2005: 187 citations2006: 190 citations2007: 217 citations2008: 183 citations2009: 162 citations2010: 153 citations2011: 201 citations2012: 215 citations2013: 248 citations2014: 334 citations2015: 430 citations2016: 504 citations2017: 492 citations2018: 422 citations2019: 1,820 citations2020: 2,537 citations2021: 2,130 citations2022: 1,520 citations2023: 1,151 citations2024: 1,673 citations2025: 609 citations2026: 42 citations1911–1985: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,594 citing papers, 21% of this breakdownUnited Kingdom: 1,710 citing papers, 7.8% of this breakdownCanada: 1,621 citing papers, 7.4% of this breakdownGermany: 1,366 citing papers, 6.2% of this breakdownItaly: 1,350 citing papers, 6.2% of this breakdownChina: 1,106 citing papers, 5.1% of this breakdownNetherlands: 910 citing papers, 4.2% of this breakdownFrance: 865 citing papers, 4% of this breakdownSpain: 612 citing papers, 2.8% of this breakdownSwitzerland: 550 citing papers, 2.5% of this breakdownJapan: 531 citing papers, 2.4% of this breakdownAustralia: 509 citing papers, 2.3% of this breakdown
0%21%Other 28.1%

Institutions

Fields

  • Medicine84.2%
  • Biochemistry, Genetics and Molecular Biology7%
  • Immunology and Microbiology3.3%
  • Engineering1.3%
  • Materials Science1.1%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other2.6%

Topics

  • Venous Thromboembolism Diagnosis and Management11.8%
  • Atrial Fibrillation Management and Outcomes10.8%
  • Blood Coagulation and Thrombosis Mechanisms4.7%
  • COVID-19 Clinical Research Studies3.7%
  • Antiplatelet Therapy and Cardiovascular Diseases3.3%
  • Heparin-Induced Thrombocytopenia and Thrombosis2.4%
  • Other63.3%

Coauthors

All papers

Open in search
  1. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

    Authors: Christian T. Ruff, Robert P. Giugliano, Eugene Braunwald, Elaine Hoffman, Naveen Deenadayalu, Michael D. Ezekowitz, A. John Camm, Jeffrey I. Weitz, Basil S. Lewis, Alexander Parkhomenko, Takeshi Yamashita, Elliott M. Antman - The Lancet 2013 cited by 4,971

  2. Edoxaban versus Warfarin in Patients with Atrial Fibrillation

    Authors: Robert P. Giugliano, Christian T. Ruff, Eugene Braunwald, Sabina A. Murphy, Stephen D. Wiviott, Jonathan L. Halperin, Albert L. Waldo, Michael Ezekowitz, Jeffrey I. Weitz, Jindřich Špinar, Witold Rużyłło, Mikhail Ruda, Yukihiro Koretsune, Joshua Betcher, Minggao Shi, Laura T. Grip, Shirali P. Patel, Indravadan Patel, James Hanyok, Michele Mercuri, Elliott M. Antman - New England Journal of Medicine 2013 cited by 5,126

  3. Therapeutic strategies for thrombosis: new targets and approaches

    Authors: Nigel Mackman, Wolfgang Bergmeier, George A. Stouffer, Jeffrey I. Weitz - Nature Reviews Drug Discovery 2020 cited by 387

  4. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

    Authors: Gary E. Raskob, Nick van Es, Peter Verhamme, Marc Carrier, Marcello Di Nisio, David García, Michael Grosso, Ajay K. Kakkar, Michael J. Kovacs, Michele Mercuri, Guy Meyer, Annelise Segers, Minggao Shi, Tzu‐Fei Wang, Erik Yeo, George Zhang, Jeffrey I. Zwicker, Jeffrey I. Weitz, Harry R. Büller - New England Journal of Medicine 2017 cited by 1,607

  5. Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source

    Authors: Robert G. Hart, Mukul Sharma, Hardi Mundl, Scott E. Kasner, Shrikant I. Bangdiwala, Scott D. Berkowitz, Balakumar Swaminathan, Pablo M. Lavados, Yongjun Wang, Yilong Wang, Antonio Dávalos, N. А. Shamalov, Robert Mikulík, Luís Cunha, Arne Lindgren, Antonio Araúz, Wilfried Lang, Anna Członkowska, Jens Eckstein, Rubens José Gagliardi, Pierre Amarenco, Sebastián F. Ameriso, Turgut Tatlisumak, Roland Veltkamp, Graeme J. Hankey, Danilo Toni, Dániel Bereczki, Shinichiro Uchiyama, George Ntaios, Byung‐Woo Yoon, Raf Brouns, Matthias Endres, Keith W. Muir, Natan M. Bornstein, Şerefnur Öztürk, Martin O’Donnell, Matthys M. De Vries Basson, Guillaume Paré, Calin Pater, Bodo Kirsch, Patrick Sheridan, Gary Peters, Jeffrey I. Weitz, W. Frank Peacock, Ashkan Shoamanesh, Oscar Benavente, Campbell Joyner, Ellison Themeles, Stuart J. Connolly - New England Journal of Medicine 2018 cited by 1,010

  6. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation

    Authors: Jan Steffel, Peter Verhamme, Tatjana Potpara, Pierre Albaladejo, Matthias Antz, Lien Desteghe, Karl Georg Hæusler, Jonas Oldgren, Holger Reinecke, Vanessa Roldan-Schilling, Nigel Rowell, Peter Sinnaeve, Rónán Collins, A. John Camm, Hein Heidbüchel, ESC Scientific Document Group, Gregory Y.H. Lip, Jeffrey I. Weitz, Laurent Fauchier, Deirdre A. Lane, Giuseppe Boriani, Andreas Goette, Roberto Keegan, Robert J. MacFadyen, Chern‐En Chiang, Boyoung Joung, Wataru Shimizu - European Heart Journal 2018 cited by 2,136

  7. Idarucizumab for Dabigatran Reversal — Full Cohort Analysis

    Authors: Charles V. Pollack, Paul Reilly, Joanne van Ryn, John W. Eikelboom, Stephan Glund, Richard A. Bernstein, Robert Dubiel, Menno V. Huisman, Elaine M. Hylek, CW Kam, Pieter W. Kamphuisen, Jörg Kreuzer, Jerrold H. Levy, Gordon Royle, Frank W. Sellke, Joachim Stangier, Thorsten Steiner, Peter Verhamme, Bushi Wang, Laura Young, Jeffrey I. Weitz - New England Journal of Medicine 2017 cited by 1,136

  8. Oral Apixaban for the Treatment of Acute Venous Thromboembolism

    Authors: Giancarlo Agnelli, Harry R. Büller, Alexander T. Cohen, Madelyn Curto, Alexander Gallus, Margot Johnson, Urszula Masiukiewicz, Raphael Pak, John R. Thompson, Gary E. Raskob, Jeffrey I. Weitz - New England Journal of Medicine 2013 cited by 2,283

  9. Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

    Authors: Harry R. Büller, Claudette Bethune, Sanjay Bhanot, David Gailani, Brett P. Monia, Gary E. Raskob, Annelise Segers, Peter Verhamme, Jeffrey I. Weitz - New England Journal of Medicine 2014 cited by 622

  10. Medical device‐induced thrombosis: what causes it and how can we prevent it?

    Authors: Iqbal Jaffer, James C. Fredenburgh, J. Hirsh, Jeffrey I. Weitz - Journal of Thrombosis and Haemostasis 2015 cited by 539

  11. Milvexian for the Prevention of Venous Thromboembolism

    Authors: Jeffrey I. Weitz, John Strony, Walter Ageno, David Gailani, Elaine M. Hylek, Michael R. Lassen, Kenneth W. Mahaffey, Ravi S. Notani, Robin Roberts, Annelise Segers, Gary E. Raskob - New England Journal of Medicine 2021 cited by 248

  12. Abelacimab for Prevention of Venous Thromboembolism

    Authors: Peter Verhamme, B. Alexander Yi, Annelise Segers, Janeen Salter, Daniel M. Bloomfield, Harry R. Büller, Gary E. Raskob, Jeffrey I. Weitz - New England Journal of Medicine 2021 cited by 291

  13. Parenteral Anticoagulants

    Authors: David García, Trevor Baglin, Jeffrey I. Weitz, M Samama - CHEST Journal 2012 cited by 1,064

  14. A Test in Context: D-Dimer

    Authors: Jeffrey I. Weitz, James C. Fredenburgh, John W. Eikelboom - Journal of the American College of Cardiology 2017 cited by 575

  15. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

    Authors: Behnood Bikdeli, Mahesh V. Madhavan, David Jiménez, Taylor Chuich, Isaac Dreyfus, Elissa Driggin, Caroline Der‐Nigoghossian, Walter Ageno, Mohammad Madjid, Yutao Guo, Liang Tang, Yu Hu, Jay Giri, Mary Cushman, I. Quéré, Evangelos Dimakakos, C. Michael Gibson, Giuseppe Lippi, Emmanuel J. Favaloro, Jawed Fareed, Joseph A. Caprini, Alfonso Tafur, John Burton, Dominic P. Francese, Elizabeth Wang, Anna Falanga, Claire McLintock, Beverley J. Hunt, Alex C. Spyropoulos, Geoffrey D. Barnes, John W. Eikelboom, Ido Weinberg, Sam Schulman, Marc Carrier, Gregory Piazza, Joshua A. Beckman, Philippe Gabríel Steg, Gregg W. Stone, Stephan Rosenkranz, Samuel Z. Goldhaber, Sahil A. Parikh, Manuel Monréal, Harlan M. Krumholz, Stavros Konstantinides, Jeffrey I. Weitz, Gregory Y.H. Lip - Journal of the American College of Cardiology 2020 cited by 2,939

  16. Apixaban for Extended Treatment of Venous Thromboembolism

    Authors: Giancarlo Agnelli, Harry R. Büller, Alexander T. Cohen, Madelyn Curto, Alexander Gallus, Margot Johnson, Anthony R. Porcari, Gary E. Raskob, Jeffrey I. Weitz - New England Journal of Medicine 2012 cited by 1,341

  17. Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

    Authors: Jeffrey I. Weitz, Anthonie W.A. Lensing, Martin H. Prins, Rupert Bauersachs, Jan Beyer‐Westendorf, Henri Bounameaux, Timothy Brighton, Alexander T. Cohen, Bruce L. Davidson, Hervé Decousus, Maria Cecília S. Freitas, Gerlind Holberg, Ajay K. Kakkar, Lloyd Haskell, Bonno van Bellen, Ákos F. Pap, Scott D. Berkowitz, Peter Verhamme, Philip S. Wells, Paolo Prandoni - New England Journal of Medicine 2017 cited by 768

  18. Neutrophil Extracellular Traps Promote Thrombin Generation Through Platelet-Dependent and Platelet-Independent Mechanisms

    Authors: Travis J. Gould, Trang T. Vu, Laura L. Swystun, Dhruva J. Dwivedi, Safiah H.C., Jeffrey I. Weitz, Patricia C. Liaw - Arteriosclerosis Thrombosis and Vascular Biology 2014 cited by 485

  19. Venous thrombosis

    Authors: Alisa S. Wolberg, Frits R. Rosendaal, Jeffrey I. Weitz, Iqbal Jaffer, Giancarlo Agnelli, Trevor Baglin, Nigel Mackman - Nature Reviews Disease Primers 2015 cited by 378

  20. Prognostic utility and characterization of cell-free DNA in patients with severe sepsis

    Authors: Dhruva J. Dwivedi, Lisa J. Toltl, Laura L. Swystun, Janice Pogue, Kao‐Lee Liaw, Jeffrey I. Weitz, Deborah J Cook, Alison Fox‐Robichaud, Patricia C. Liaw, the Canadian Critical Care Translational Biology Group - Critical Care 2012 cited by 313

  21. Factor XI Inhibition to Uncouple Thrombosis From Hemostasis

    Authors: Charles Hsu, Edward Hutt, Daniel M. Bloomfield, David Gailani, Jeffrey I. Weitz - Journal of the American College of Cardiology 2021 cited by 173

  22. Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty

    Authors: Jeffrey I. Weitz, Rupert Bauersachs, Bastian Becker, Scott D. Berkowitz, Maria Cecília S. Freitas, Michael R. Lassen, Carola Metzig, Gary E. Raskob - JAMA 2020 cited by 249

  23. Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19

    Authors: Alex C. Spyropoulos, Mark Goldin, Dimitrios Giannis, Wassim Diab, Janice Wang, Sameer Khanijo, Andrea Mignatti, Eugenia Gianos, Marc Cohen, Gulru Sharifova, J Lund, Alfonso Tafur, Paul A. Lewis, Kevin P. Cohoon, Husneara Rahman, Cristina Sison, Martin Lesser, Kanta Ochani, Nirav Agrawal, Judith Hsia, Victoria E. Anderson, Marc P. Bonaca, Jonathan L. Halperin, Jeffrey I. Weitz, HEP-COVID Investigators, Lori Ohanesian, Michelle Glater, Christopher C.K. Ho, Annamaria Iakovou, Daniel Ying, Manile Dastagir, Alex Convissar, Seerat Aujla, Elizabeth Mathew, Vani Thiyagarajan, Tricia Lewis, Luis Gruberg, Paul Maccaro, Dana Kuziw, Bhumi Pandhi, George Surguladze, Ashley M. Eapen, A. Pantea, PHYLLIS SUEN, John P. Flynt, Michael Krzyzak, Kamal Sharma, Amanda Steadham, Sherry McLean, Karen Herring, Karen Maroney, Kambiz Zorriasateyn, Bernardo Vargas‐Leitón, Marisa Durante, Ujala Bhokary, Linda Pierchala, Elizabeth A. Fisher, Debi L. Oxenberg, Alison Sabados, Omair A. Chaudhary, Shelley Schultz, S. Cotey, Connie N. Hess, Hope Cruse, Daniel Uy, Sunita Sharma, Kevin Molina, Daliya Jagat, Bandyopadhyay Dehali - JAMA Internal Medicine 2021 cited by 486

  24. Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis

    Authors: Faizan Khan, Alvi Rahman, Marc Carrier, Clive Kearon, Jeffrey I. Weitz, Sam Schulman, Françis Couturaud, Sabine Eichinger, Paul A. Kyrle, Cecilia Becattini, Giancarlo Agnelli, Timothy Brighton, Anthonie W.A. Lensing, Martin H. Prins, Elham Sabri, Brian Hutton, L. Pinède, Mary Cushman, Gualtiero Palareti, George A. Wells, Paolo Prandoni, Harry R. Büller, Marc Rodger - BMJ 2019 cited by 313